Sep 10 |
Centessa stock jumps 10% on Phase 1 narcolepsy study for ORX750
|
Sep 10 |
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
|
Sep 10 |
Investors are waking up to Centessa’s sleepiness drug
|
Sep 10 |
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
|
Aug 27 |
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
|
Aug 24 |
Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ...
|
Aug 21 |
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
Aug 19 |
Centessa Pharmaceuticals plc's (NASDAQ:CNTA) high institutional ownership speaks for itself as stock continues to impress, up 18% over last week
|
Aug 13 |
Centessa Pharmaceuticals GAAP EPS of -$0.40
|
Aug 13 |
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
|